To investigate the treatment value and clinical significance of ultrasound-guided core-needle biopsy assistance with BI-RADS categories with elasticity strain ratio in breast carcinoma of 177 cases in quantitation

doi:10.3969/.issn.1674-3245.2018.02.008

Abstract：Objective To evaluate the clinical significance of ultrasound-guided core-needle biopsy(US-CNB)in the diagnosis of breast masses for categories 4B and 4C in a validation study of 177 cases at the second edition of the Breast Imaging Reporting and Data System(BI-RADS).Methods The pathological characteristics of 177 patients with breast masses who underwent ultrasound elastography strain ratio(ESR)correction and US-CNB in the department of ultrasonography at Nanjin Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine from Sept 2014 to Sept 2016 were retrospectively analyzed. Each patient was evaluated with postoperative pathology as the gold standard. Results In a series screening of ESR and US-CNB in the 177 patients,117 cases were diagnosed with breast cancer,and 60 cases had benign masses. Finally,122 cases were confirmed with breast cancer,and 55 cases had benign lesions according to postoperative pathology. As we demonstrated here,the final study findings show that 117 cases of US-CNB were consistent with the results of postoperative pathology with breast cancer. However,5 of 60 patients had benign lesions on US-CNB,of which reported types sclerosing adenosis, ductal papillary neoplasm and fibroadenomas were confirmed as breast carcinomas on postoperative pathology, with the categories of DCIS with microinvasion,invasive ductal carcinoma,mucous carcinoma,invasive papillary carcinoma and metaplastic carcinoma. The clinical validation value of specificity of US-CNB in the diagnosis of breast carcinoma for categories 4B and 4C was 100%. Simultaneously,the sensitivity,accuracy,false-negative rate and false-positive rate for categories 4B and 4C were 94.82% and 96.88%,96.77% and 97.62%,5.17% and 3.12%, respectively, and 0%. Conclusion The clinical validation value of the BI-RADS ESR and US-CNB in the diagnosis of breast carcinoma for categories 4B and 4C with respect to the specificity,sensibility and accuracy is worthy of affirmation of the significant differences(P < 0.05,P < 0.01). As an accurate diagnosis and treatment technology,it provides an accurate pathological basis and important information for clinical follow-up treatment and prognosis.